![Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bf27a8f33dc1177ab0c7cf3c2adec21f5727b20d/3-Table1-1.png)
Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar
![Blood ovarian cancer marker test. CA 125. Uterus, ovary with a tumor. Vector medical illustration. White background. Stock Vector | Adobe Stock Blood ovarian cancer marker test. CA 125. Uterus, ovary with a tumor. Vector medical illustration. White background. Stock Vector | Adobe Stock](https://as2.ftcdn.net/v2/jpg/02/57/87/91/1000_F_257879110_YXeX5zXJVj9dHFHjP6uDWg7AJPUrKkkj.jpg)
Blood ovarian cancer marker test. CA 125. Uterus, ovary with a tumor. Vector medical illustration. White background. Stock Vector | Adobe Stock
![What Do You Need To Know About CA 125 Ovarian Cancer Marker | TRUTEST Laboratories Powered By iGenetic Diagnostics What Do You Need To Know About CA 125 Ovarian Cancer Marker | TRUTEST Laboratories Powered By iGenetic Diagnostics](https://www.trutestlab.com/uploads/blog/medium/Cancer-treatment_1627031240.jpg)
What Do You Need To Know About CA 125 Ovarian Cancer Marker | TRUTEST Laboratories Powered By iGenetic Diagnostics
![Frontiers | Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors Frontiers | Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors](https://www.frontiersin.org/files/MyHome%20Article%20Library/694441/694441_Thumb_400.jpg)
Frontiers | Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors
![Risk of ovarian cancer in women with symptoms in primary care: population based case-control study | The BMJ Risk of ovarian cancer in women with symptoms in primary care: population based case-control study | The BMJ](https://www.bmj.com/content/bmj/339/bmj.b2998/F2.large.jpg)
Risk of ovarian cancer in women with symptoms in primary care: population based case-control study | The BMJ
![Review of Ovarian Tumors in Children and Adolescents: Radiologic-Pathologic Correlation | RadioGraphics Review of Ovarian Tumors in Children and Adolescents: Radiologic-Pathologic Correlation | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.347130144/asset/images/medium/rg.347130144.tbl2.gif)
Review of Ovarian Tumors in Children and Adolescents: Radiologic-Pathologic Correlation | RadioGraphics
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.fig13.gif)
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity | PLOS ONE
![Ovarian Cancer Tumor Marker Ca125 Stock Photo - Download Image Now - Cancer - Illness, Blood, Breast Cancer - iStock Ovarian Cancer Tumor Marker Ca125 Stock Photo - Download Image Now - Cancer - Illness, Blood, Breast Cancer - iStock](https://media.istockphoto.com/id/1060233252/photo/ovarian-cancer-tumor-marker-ca-125.jpg?s=1024x1024&w=is&k=20&c=f7XqgIzCxFe4eZO6dYrX4BUJfDR1Xao_nuKqlR5FUzQ=)